Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07627529 · ClinicalTrials.gov registry record · Phase 4
Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson Disease
A Phase 4 study, sponsored by Corporal Michael J. Crescenz VA Medical Center.
- Not yet
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT07627529 is a Phase 4 study that has not yet begun recruiting, run by Corporal Michael J. Crescenz VA Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT07627529, a Phase 4 study, has not yet begun recruiting, sponsored by Corporal Michael J. Crescenz VA Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is an unblinded, non-randomized National Institute of Health (NIH) Stage I of Behavioral Intervention Development trial. The investigators will enroll 20 subjects with Parkinson disease (PD) for a series of 20 of N-of-1 trials. The investigators will use a single-arm crossover titration/reversal design ("ON" \[A\] vs. "OFF" \[B\]) with up to 4 periods. All participants will follow the sequence ABAB. Each period will last up to 10 weeks, allowing for sufficient time for up-titration and onset of drug action, and down-titration and washout. Each participant will have the option to participate in less (2-3) or more (3-4) periods depending on whether additional information is needed to make an informed decision about continuing or discontinuing the overactive bladder (OAB) antimuscarinic at the end of the study. The intervention drug will be an OAB antimuscarinic, previously prescribed to the participants by their physician. The investigators will reduce the dose of each OAB antimuscarinic by 25-50% every 1-2 weeks during the "OFF" \[B\] period, with the goal to completely discontinue the medication.
Interventions
- DRUG Overactive bladder antimuscarinic deprescribing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07627529
The ClinicalTrials.gov registry entry for NCT07627529 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corporal Michael J. Crescenz VA Medical Center, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Overactive bladder antimuscarinic deprescribing is the first listed.
NCT07627529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07627529 about?
NCT07627529 is a clinical study titled "Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson Disease". This is an unblinded, non-randomized National Institute of Health (NIH) Stage I of Behavioral Intervention Development trial. The investigators will enroll 20 subjects with Parkinson disease (PD) for a series of 20 of N-of-1 trials. The investigators will use a single-arm crossover titration/reversa...
What is the current status of trial NCT07627529?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2026-06. Estimated completion is 2027-04.
What interventions are being tested in trial NCT07627529?
The interventions under investigation include: Overactive bladder antimuscarinic deprescribing (DRUG).
Who is sponsoring clinical trial NCT07627529?
This trial is sponsored by Corporal Michael J. Crescenz VA Medical Center, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.